DeQuan Kuntu

Mapped Northeast accounts across AMCs, outpatient imaging networks, trauma systems, and VA facilities by access pathway and deployment motion. Finding: MRI imaging centers represent the shortest-cycle opportunities and should be prioritized early.

Mapped key Northeast KOLs across radiology, urology, neurology, oncology, and neurosurgery. Anchor: Ana Franceschi MD PhD (Lenox Hill / Northwell, Cortechs MAB). OnQ Prostate: Daniel Margolis (Weill Cornell), Eric Weinberg (URMC). Plus durable Northeast network carried in from Dilon, Counsyl, Stratocore.

Northeast accounts mapped by scanner installed base. Philips-anchored: BIDMC, McLean, RadNet sites. Siemens-anchored: Mount Sinai, NYU. GE-anchored: Mass General Brigham, Yale, Hopkins, Penn (GE acquired competitor icometrix in Sept 2025 — these are competitive-risk accounts). Finding: Philips + Siemens alignment through Cortechs creates lower-friction entry across several Northeast academic accounts.

Mapped stakeholder motivations and gatekeeping patterns across clinical, operational, administrative, governance, and economic buyers. Early pattern: radiology consistently emerged as the primary buyer and operational decision-maker. Other specialties — urology, neurology, trauma, ED — can influence and pull demand, but the radiology read and the radiology budget are where adoption is won or lost.

Direct (icometrix → GE Sept '25, Quibim, Combinostics, QMENTA), enterprise platform (Aidoc), and adjacent lanes (Cleerly, HeartFlow, Subtle Medical, Clairity). What stands out commercially: the combination of quantitative MRI heritage, Philips/Siemens marketplace presence, RSI on prostate, and broad deployment scale vs. icometrix 300+.

Multi-parametric prostate MRI + PI-RADS + RSI/RSM/CFM, ARIA monitoring workflow (Leqembi/Kisunla), and CT brain protocols across stroke, trauma, and post-surgical use. Finding: Cortechs' own peer-reviewed evidence — and broader research on radiologist burnout and read-quality variability — is a lever I'd use to elevate the conversation from a departmental tool purchase to a C-suite quality-and-throughput discussion.

Additional channel opportunities identified: grand rounds and tumor boards where physicians present cases and name the AI tool out loud — the fastest way for more clinicians to know Cortechs by name when it's used; reference-site cultivation (one practice grew from 3 prostate MRIs a month to 5 a week); a two-anchor model pairing a physician champion with an operations lead; fellowship rotation pipelines; manufacturer-led joint calls; pharma co-marketing (Eisai/Lilly); business-development partnerships; and accredited continuing-education events.

Direct outreach to 15+ physicians to pressure-test adoption assumptions — field validation, not desktop research. A few asked to talk in person; several said imaging AI is "all radiology"; not many knew Cortechs by name yet, but all agreed AI is becoming a growing part of radiology. Highlights (more responses still coming in): • Dr. D.C., Radiology, University of Miami — strongly in favor of AI tools and uses them regularly; University of Miami is an active Cortechs opportunity. Away currently, but open to a deeper conversation on his return. • Dr. H.C., Trauma Surgery, NYC Health + Hospitals — open to further conversation; the questions prompted him to want to ask his own radiologists what AI they're currently using. • Dr. J.B., Trauma Surgery, Johns Hopkins — uses AI tools on the trauma side but has limited visibility into what runs on the radiology side. His question captures the core integration issue: "An early interpretation is always better, but surely the AI needs to be integrated into our EMR?" • Dr. B.V.F., Emergency Medicine, Ascension Alexian Brothers — described years of radiology-quality decline at his hospital tied to cost-cutting and repeated rad-group turnover. His read: AI is the logical next step, but a cost-constrained owner and a high-malpractice market (Cook County) make adoption hard. He also raised broader concerns about AI's impact on radiology and the economic pressures facing hospital systems. My framing for that conversation: Cortechs is positioned to empower radiologists, not replace them — consistent, quantified reads that reduce variability and help lower malpractice exposure in exactly the markets he's describing. • Personal contact under Dr. Ted Rothstein (GWU) — published Cortechs research author (PPMS, MS gray/white matter); shared NeuroQuant scan firsthand. Finding: the radiologist is the buyer, but the use case currently lives quietly inside the radiology reporting flow — downstream clinicians benefit without visibility, integration into the EMR is the recurring practical question, and in cost-constrained or high-malpractice systems the economic and liability case is the true gate. Opportunity worth testing: making the platform clinically visible — physicians naming Cortechs in tumor boards and grand rounds — could convert passive beneficiaries into active advocates and accelerate academic-center adoption through peer influence. (I'll continue reporting back as more physicians respond.)

I work the territory across five motions: clinical trust earns the right to compete; workflow adoption converts trial into repeat use; referral demand often begins before imaging is even ordered; economic and executive approval green-lights or stalls; reimbursement and channel strategy compound the territory over time. Most deals stall when one motion is unattended — I work all five in parallel.